Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis [0.03%]
校正：系统评价和事后分析中给药后裸盖菇素的临床药代动力学
Marije E Otto,Katelijne V van der Heijden,Jan W Schoones et al.
Marije E Otto et al.
Published Erratum
Clinical pharmacokinetics. 2025 Feb 21. DOI:10.1007/s40262-025-01487-3 2025
Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes [0.03%]
艾本格lutide阿尔法在健康受试者和二型糖尿病受试者中的群体药代动力学研究
Yan-Ru Lou,Yu-Long Xu,Yifeng Xiong et al.
Yan-Ru Lou et al.
Background and objectives: Efsubaglutide alfa is a novel long-acting human glucagon-like peptide-1 receptor agonist. Clinical studies in patients with type 2 diabetes (T2D) have shown excellent glucose-lowering effects. T...
Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity [0.03%]
不同肥胖程度的非瓣膜性房颤患者直接口服抗凝药血药浓度差异分析
Danilo Menichelli,Arianna Pannunzio,Erminia Baldacci et al.
Danilo Menichelli et al.
Background: Atrial fibrillation (AF) has multiple cardio-metabolic comorbidities, including obesity. The use of direct oral anticoagulants (DOACs) in patients with AF and obesity is still uncertain owing to the concern of...
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics [0.03%]
肝功能损害对恩曲替尼药代动力学影响的临床探究及基于生理的建模
Agustos C Ozbey,Georgina Meneses-Lorente,Brian Simmons et al.
Agustos C Ozbey et al.
Background and objectives: This study investigates the pharmacokinetics (PK) of entrectinib and its metabolite M5 (CYP3A4 substrates) in patients with hepatic impairment (HI) and applies physiologically based pharmacokine...
Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib [0.03%]
柯替瑞的药物代谢动力学及其对抗癌药奥拉帕尼药物代谢动力学的影响
Joanneke K Overbeek,Nielka P van Erp,David M Burger et al.
Joanneke K Overbeek et al.
Objectives: Pharmacokinetic (PK) boosting is the intentional use of strong inhibitors of metabolic enzymes or transporters to boost the systemic exposure of a therapeutic drug. PK boosting is expanding to therapeutic area...
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease [0.03%]
APOE4阳性的早期阿尔茨海默病患者的口服ALZ-801/valiltramiprosate II期临床试验中的药物临床动力学研究
John A Hey,Jeremy Y Yu,Susan Abushakra et al.
John A Hey et al.
Introduction: ALZ-801/valiltramiprosate is an oral, small-molecule inhibitor of β-amyloid (Aβ) oligomer formation in late-stage development as a potential disease-modifying therapy for Alzheimer's disease (AD). ALZ-801,...
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten [0.03%]
肝功能或肾功能不全对Aficamten药代动力学的影响
Donghong Xu,Justin D Lutz,Punag Divanji et al.
Donghong Xu et al.
Background and objective: Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily elimi...
Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs [0.03%]
通过简化PBPK模型识别BCS II/IV类药物的溶出限制吸收以预测餐食效应
Karine Rodriguez-Fernandez,José David Gómez-Mantilla,Suneet Shukla et al.
Karine Rodriguez-Fernandez et al.
Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs [0.03%]
BCS II/IV药物阳性食物效应预测的溶解性限制吸收评价研究
Karine Rodriguez-Fernandez,José David Gómez-Mantilla,Suneet Shukla et al.
Karine Rodriguez-Fernandez et al.
Introduction and objective: Physiologically based pharmacokinetic (PBPK) models are increasingly used to predict food effect (FE) but model parameterization is challenged by in vitro-in vivo (IVIV) disconnect and/or param...
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis Therapy [0.03%]
利福平及其代谢产物25-脱乙酰基利福平的暴露量在结核病治疗早期迅速下降
Sylvain Goutelle,Olivier Bahuaud,Charlotte Genestet et al.
Sylvain Goutelle et al.
Background and objective: Limited information is available on the pharmacokinetics of rifampicin (RIF) along with that of its active metabolite, 25-deacetylrifampicin (25-dRIF). This study aimed to analyse the pharmacokin...